Pancreatic Cancer

The prognosis for patients with advanced pancreatic cancer (stage III or higher) remains dire even after curative resection. Liver metastasis or local reoccurrence appears in most patients. Impairment of the immune system is decidedly a factor, due to the advancement of the cancer itself. Furthermore, impairment of the immune system occurs during the postoperative period.

Despite even radical resections, residual regional tumor cells remain a threat. AAIT can be augmented as a viable treatment option intended to marginalize micro and macro metastatic cells where chemotherapy has failed in the past. The effectiveness of prior published lesser immunotherapy strategies for this cancer type has shown that treatment was beneficial, heralding a positive survival. Envita's AAIT is deemed a future generation immunotherapy that enables a direct anti-metastatic treatment that affects primary site and regional metastasis. In clinical observation, the earlier the patient initiates treatment, in conjugation with concurrent enzymatic treatment, said patients experience the most favorable outcomes.

Overview AAIT with Pancreatic Cancers

  • Direct anti-tumor approach, independent of chemotherapy, surgery and radiotherapy.
  • Assistance in postoperative treatment to treat metastatic cancer cells, poised to block acceleration of growth, typically seen postoperatively due to increased tumor growth factors.
  • Innovative customized strategy for those pancreatic patients with metastatic spread to the liver.
  • In particular cases intraportal AAIT can be appropriated to prevent local regional reoccurrence in patients seeking curative resection of pancreatic cancer.


Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer. M. Kobari, S. Egawa, K. Shibuya, M. Sunamura, K. Saitoh and S. Matsuno First Department of Surgery, Tohoku University of Medicine, 1-1 Seiryo-machi, Aoba-Ku, Dendai 980-8574, Japan

Get in contact with us!

Welcome to Envita's Biologics Division! Our AAIT method is the latest in our line of cancer and immunotherapy treatments and in comparison to immunotherapy options that are currently available in United States as well as abroad, it boasts a significant level of tumor kill without having to resort to biopsy. AAIT can be used in addition to chemotherapy, radiotherapy and/or delivered intra-operatively. It's very important to note that AAIT can also be utilized completely independent of chemotherapy and radiation because it leverages a completely different mechanism of tumor kill. If you have any questions or would like to speak to our clinicians directly, please send us an email. To learn more about how you or your institution can become part of our Envita Mexico team, please don't hesitate to contact us.

Toll Free: 1.866.830.4576
Phone: 602.569.4144

Your message has been sent!